GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Valuation Rank

CanSino Biologics (HKSE:06185) Valuation Rank


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


CanSino Biologics Valuation Rank Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


CanSino Biologics Business Description

Traded in Other Exchanges
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.
Executives
Yu Xuefeng 2501 Other
Chao Shou Bai 2202 Interest of your spouse
Mao Helen Huihua 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2201 Interest of corporation controlled by you
Qm29 Limited 2101 Beneficial owner
Qiu Dongxu 2501 Other
Zhu Tao
Orbimed Capital Llc 2102 Investment manager